Gout-Biochemical basis
Biochemical Basis of Gout
Biochemical Basis of Gout
Gout
develops due to hyperuricemia —
an abnormally high level of uric acid
in the blood.
1. Uric Acid Formation (Purine Metabolism)
- Uric
acid is
the end product of purine
metabolism in humans.
- Purines (adenine & guanine)
from dietary intake, cell turnover, or DNA/RNA degradation or broken
down.
- The degradation pathway for
purines involves the following steps:
- Adenosine
and Guanosine Breakdown:
- Adenosine → Hypoxanthine →
Xanthine
- Guanosine → Xanthine
- Formation
of Uric Acid:
- Xanthine is converted to uric acid by the enzyme xanthine oxidase.
- The key enzyme involved is:
- Xanthine
oxidase,
which converts:
- Hypoxanthine → Xanthine → Uric acid
2. Causes of Hyperuricemia
Hyperuricemia,
the primary cause of gout, occurs due to:
- Overproduction
of Uric Acid:
- Increased purine intake (e.g.,
meat, seafood, alcohol).
- Enhanced cell turnover (e.g.,
in cancer or psoriasis).
- Genetic mutations affecting
enzymes in purine metabolism:
- Hypoxanthine-Guanine
Phosphoribosyltransferase (HGPRT) deficiency in Lesch-Nyhan syndrome.
- Phosphoribosyl
Pyrophosphate Synthetase (PRPP) hyperactivity.
- Underexcretion
of Uric Acid:
- Reduced renal clearance
(common in kidney dysfunction).
- Use of medications like
diuretics and aspirin.
Conditions
like metabolic syndrome or dehydration.
3. Crystal
Deposition and Inflammation
- When uric acid exceeds its
solubility limit, monosodium urate
crystals form.
- These crystals deposit in synovial joints, triggering an immune response.
- Neutrophils ingest the crystals, releasing
inflammatory mediators → causes acute
inflammation.
4. Biochemical Basis of Uric Acid Regulation
- Key Enzymes:
- Xanthine
Oxidase:
Converts hypoxanthine and xanthine to uric acid.
- HGPRT: Recycles purines by
converting hypoxanthine to IMP and guanine to GMP.
- PRPP
Synthetase:
Catalyzes the production of PRPP, a precursor in purine biosynthesis.
- Kidney
Excretion:
- Uric acid is filtered by the
glomerulus, reabsorbed by the proximal tubule, and partially secreted
back into the urine.
5. Clinical Manifestations
- Pain and swelling in joints
(especially the big toe, known as podagra).
- Formation of tophi in chronic cases.
- Kidney stones due to uric acid
crystallization in the urinary tract.
6. Diagnosis
- Elevated serum uric acid levels
(>6.8 mg/dL).
- Identification of MSU crystals
in joint aspirate (needle-shaped and negatively birefringent under
polarized light).
7. Treatment (Biochemical Focus)
|
Drug |
Target |
Effect |
|
Allopurinol |
Inhibits xanthine oxidase |
↓ Uric acid production |
|
Febuxostat |
Also inhibits xanthine oxidase |
Used when allopurinol is not
tolerated |
|
Colchicine |
Blocks neutrophil activity |
Reduces inflammation during acute
gout attack |
|
Probenecid |
Increases uric acid excretion |
Used in underexcretors |
Summary
- Gout
= Too much uric acid → crystals in joints → pain and inflammation
- Caused by purine metabolism imbalance
- Involves key enzymes like xanthine oxidase and HGPRT
- Treated by reducing uric acid production or
increasing its excretion
Comments
Post a Comment